UroGen's Chief Medical Officer Sold $400,000 in Stock After a 191% Run

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• Sold 10,000 ordinary shares of UroGen Pharma Ltd. for a total value of $400,000 on July 9, 2026.

  60% confidence

• The sale was conducted under a pre-established Rule 10b5-1 trading plan adopted on August 15, 2025, which provides for automated execution and represents the concluding transaction of that plan's schedule.

  60% confidence

• UroGen Pharma reported trailing 12-month revenue of $140.5 million and a net loss of $133.2 million.

  60% confidence

• UroGen Pharma is a commercial-stage biotechnology company with a $2 billion market capitalization, demonstrating significant growth momentum with a one-year stock appreciation of 191.31%.

  60% confidence

Cited in these Via News reports

• Biotech Grows Up: A Phase 3 Win, a Profitable Incyte and Royalty Income, While the Early Pipeline and AI Drugs Still Have to Prove Themselves →